



# In vitro growth inhibition of human cancer cells by novel honokiol analogs

Jyh Ming Lin<sup>a,\*</sup>, A.S. Prakasha Gowda<sup>a,†</sup>, Arun K. Sharma<sup>b</sup>, Shantu Amin<sup>b</sup>

<sup>a</sup> Department of Biochemistry & Molecular Biology, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA

<sup>b</sup> Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA

## ARTICLE INFO

### Article history:

Received 13 October 2011

Revised 19 March 2012

Accepted 27 March 2012

Available online 3 April 2012

### Keywords:

Honokiol analogs

Cell proliferation

CDK1

Cyclin B1

Human cancer cell

## ABSTRACT

Honokiol possesses many pharmacological activities including anti-cancer properties. Here in, we designed and synthesized honokiol analogs that block major honokiol metabolic pathway which may enhance their effectiveness. We studied their cytotoxicity in human cancer cells and evaluated possible mechanism of cell cycle arrest. Two analogs, namely **2** and **4**, showed much higher growth inhibitory activity in A549 human lung cancer cells and significant increase of cell population in the G0–G1 phase. Further elucidation of the inhibition mechanism on cell cycle showed that analogs **2** and **4** inhibit both CDK1 and cyclin B1 protein levels in A549 cells.

© 2012 Elsevier Ltd. All rights reserved.

## 1. Introduction

Honokiol is one of the biphenolic constituent isolated from the stem bark and root of *Magnolia officinalis*,<sup>1</sup> a Chinese medicine used to treat variety of diseases. It is shown to possess many pharmacological activities, including anti-inflammatory,<sup>2</sup> anti-thrombosis,<sup>3</sup> antioxidant effects,<sup>4</sup> antiviral,<sup>5,6</sup> and induce differentiation in HL-60 human leukemia cells.<sup>7</sup> Studies have demonstrated that honokiol induces apoptosis in several cell types such as human colorectal,<sup>8</sup> rat hepatic stellate,<sup>9</sup> human squamous lung cancer<sup>10</sup> and B cell chronic lymphocytic leukemia cells.<sup>11</sup> In addition, honokiol inhibits skin tumor promotion,<sup>12</sup> human fibrosarcoma invasiveness in vitro,<sup>13</sup> angiogenesis and tumor growth in vivo,<sup>14</sup> and overcomes drug resistance in multiple myeloma.<sup>15</sup> More recently, honokiol has also been shown to act as chemopreventive agent against UVB induced skin cancer in a hairless mouse model.<sup>16</sup> Saibokuto, a traditional Chinese remedy containing honokiol<sup>17</sup> as major ingredient, is approved as effective treatment for asthma and bronchitis by Japanese Health Ministry.

Honokiol is reported to induce cell cycle arrest at G0/G1 phase in human prostate cancer cell and vascular muscle smooth cells.<sup>18,19</sup> It also suppresses osteoclastogenesis and invasion through modulation of NFκB pathway.<sup>20</sup> Honokiol has been shown to interact with cell cycle regulatory proteins such as cyclin-dependent kinases (CDKs) and cyclins;<sup>16,20</sup> it down-regulates the levels of cyclins D1, D2, E and associated CDK2, CDK4 and CDK6. In the

last decade, there is growing evidence to challenge the classical view of cell cycle regulation.<sup>21</sup> Recent investigation on genetic and RNA interference in mammalian cells have reported that CDK2 and CDK4 are not necessary for cell cycle progression, and CDK1 as the only nonredundant cell cycle driver.<sup>22,23</sup> Several natural and synthetic small molecule inhibitors have been reported, but cell cycle studies of these molecules are not consistent with specific CDK1 inhibition.<sup>24,25</sup> Cyclin B1 is essential for the initiation of mitosis. It accumulates in the S phase of the cell cycle and reaches the maximal level at mitosis, but is absent in G1 phase cells.<sup>26</sup> However, recent reports indicated that cyclin B1 was expressed in the G1 phase in several synchronized and asynchronously growing cancer cells.<sup>27–31</sup> Furthermore, over expression of cyclin B1 has been reported in tumor cells,<sup>32–35</sup> thus targeting cyclin B1 and its complex partner, namely CDK1 is a promising therapeutic approach for controlling cancer.

There are reports of structure–activity relationship (SAR) studies on honokiol; allyl substituted biphenyl skeleton seems to be common element in these studies.<sup>6,14,36</sup> However, the end points of these studies vary widely; therefore no concrete conclusion could be drawn. We were interested in designing novel analogs of honokiol, which could follow a similar mechanism as honokiol but are more potent, by careful manipulation of the functional groups. Our hypothesis for SAR study was that the hydroxyl groups on the honokiol biphenyl skeleton may be subjected to metabolic oxidation by phase I enzymes,<sup>37,38</sup> and subsequently excrete out of the system, therefore might reduce its effectiveness. Glucuronidation and sulfation of the free hydroxyl groups have been shown to be the main metabolic pathways for honokiol in rat and human liver leading to a faster excretion and reduced half-life.<sup>39</sup> Therefore,

\* Corresponding author. Tel.: +1 717 531 3612; fax: +1 717 531 7072.

E-mail address: [jml47@psu.edu](mailto:jml47@psu.edu) (J.M. Lin).

† These authors contributed equally to this work.

we synthesized several honokiol analogs (Fig. 1), which have their 4'-hydroxyl group replaced with methoxy group in A-ring, and the substitution pattern of allyl and hydroxyl groups in B-ring altered, in order to study their cytotoxicity and mechanism of action.

In this study, we explore the SAR of honokiol analogs for their cytotoxicity in human lung (A549), melanoma (UACC903) and colon (HT-29) cancer cell lines and determine the underlying mechanism of action by evaluating the cell cycle studies of honokiol analogs **2** and **4**, the two best identified analogs based on their potent inhibition of A549 human lung cancer cell growth.

## 2. Experimental section

**Reagents.** All chemicals for the syntheses were obtained from Aldrich Chemical Co. (St. Louis, MO) and used without further purification. Thin-layer chromatography (TLC) was developed on aluminum-supported pre-coated silica gel plates (EM industries, Gibbstown, NJ). Column chromatography was performed on silica gel (70–230 mesh). NMR spectra were recorded on Bruker Avance II 500 MHz instrument and the chemical shifts are given as  $\delta$  values with reference to tetramethylsilane (TMS) as internal standard. MS spectra were recorded on Applied Biosystems API 3200. Honokiol was supplied by Sigma–Aldrich. Stock solution of honokiol and its analogs (final concentration, 10 mM) was prepared in DMSO, stored at  $-20^{\circ}\text{C}$ , and diluted with fresh complete medium immediately before use. DMEM was from Mediatech, Inc.; trypsin–EDTA solution was from Invitrogen, and fetal bovine serum was from Atlanta Biological. Protease inhibitor cocktail was from BD Biosciences, propidium iodide was from Sigma. Polyclonal antibodies to cyclin B1 and cyclin-dependent kinase 1 (CDK1) were from Millipore, and protease inhibitor from Thermo Scientific, USA.

### 2.1. Synthesis of honokiol analogs

#### 2.1.1. Syntheses of key components of Suzuki coupling reagents

**2.1.1.1. 4-Allylphenol (7).** 4-Allylanisole (20 g, 135 mmol) was dissolved in 400 ml of  $\text{CH}_2\text{Cl}_2$  and cooled by ice bath under

nitrogen atmosphere,  $\text{BBr}_3$  (37.2 g, 148.5 mmol) was added through double needle. The mixture was stirred for 3 h at  $0^{\circ}\text{C}$  then was allowed to warm up to room temperature over night. The mixture was poured to ice water and organic layer separated. The aqueous layer was extracted with  $\text{CH}_2\text{Cl}_2$  (100 ml  $\times$  3). The combined organic layer was dried over  $\text{Na}_2\text{SO}_4$ , solvent was evaporated to yield 19.2 g black oily residue. Crude compound (7.55 g) was purified by column chromatography eluted with hexanes/EtOAc = 20/1 to yield 5.04 g 4-allylphenol (**7**) as clear oily residue (70.9%).<sup>40</sup>  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.10 (2H, dt,  $J$  = 8.50 Hz,  $J$  = 2.0 Hz), 6.82 (2H, dt,  $J$  = 8.5 Hz,  $J$  = 2.0 Hz), 6.04–5.96 (1H, m), 5.19 (1H, s), 5.13–5.09 (2H, m), 3.37 (2H, d,  $J$  = 6.5 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  153.68, 137.87, 132.41, 129.78, 115.53, 115.33, 39.35.

**2.1.1.2. 4-Allyl-2-bromo-phenol (8).** 4-Allylphenol (**7**; 1.35 g; 10.06 mmol) dissolved in 300 ml of dry diethyl ether under nitrogen atmosphere was cooled with acetone-dry ice bath. To the reaction mixture, *i*-propyl magnesium chloride (2.0 M; 5.2 ml; 10.4 mmol) was added dropwise over 3 min, and mixture was stirred at  $-78^{\circ}\text{C}$  for 1 h before 1,3-dibromo-5,5-dimethylhydantoin<sup>41</sup> (DBDMH; 1.44 g; 5.04 mmol) was added. The mixture was stirred 20 h at  $-78^{\circ}\text{C}$  then warmed up to room temperature over 1 h; then 10 ml of 10%  $\text{NaSO}_3$  was added to the mixture. The aqueous layer was extracted with ether (10 ml  $\times$  3), and the combined organic layer was dried over  $\text{Na}_2\text{S}_2\text{O}_4$ ; then concentrated in vacuo to yield 1.40 g yellowish oil as crude product. The residue was purified by flash column chromatography on silica gel eluted with hexanes/EtOAc = 40/1 to give **8** as colorless oil (0.98 g, 45.7%).<sup>40</sup>  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.31 (2H, d,  $J$  = 2.0 Hz), 7.07 (1H, dd,  $J$  = 8.5 Hz,  $J$  = 2.0 Hz), 6.98 (1H, d,  $J$  = 8.50 Hz), 5.98–5.91 (1H, m), 5.45 (1H, s), 5.13–5.08 (2H, m), 3.33 (2H, d,  $J$  = 7.0 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  150.56, 137.03, 133.74, 131.79, 129.39, 116.17, 115.94, 110.08, 38.96. MS ( $m/z$ , Intensity): 214 ( $\text{M}+1^+$ , 25%), 113 (100%), 105 (80%).

**2.1.1.3. 4-Allyl-2,6-dibromophenol (9).** 4-Allylphenol (**7**; 1.01 g, 7.45 mmol) was dissolved in 25 ml of  $\text{CHCl}_3$  at room temperature, 1,3-dibromo-5,5-dimethylhydantoin<sup>41</sup> (DBDMH; 2.24 g,




Figure 1. Structure of honokiol analogs.

7.83 mmol) was added in three portion over 5 min. The resulting mixture was stirred for 2 h; the solid was removed by filtration. The organic layer was evaporated in vacuo. The yellow residue was purified by flash column chromatography eluted with hexanes/EtOAc = 20/1 to give **9** as yellowish oil residue (1.1 g, 50.6%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.29 (2H, s), 5.95–5.88 (1H, m), 5.78 (1H, s), 5.15–5.09 (2H, m), 3.36 (2H, d,  $J$  = 6.5 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  147.66, 136.20, 134.68, 132.02, 116.88, 109.67, 38.62. MS ( $m/z$ , Intensity): 294 ( $M^+$ , 100%), 213 (5%).

**2.1.1.4. 2-Allyl-4-bromophenol (10).** 4-Bromophenol was converted to the corresponding allyl 4-bromophenyl ether. The allyl ether was then undergoing thermal rearrangement according procedure described by Sviridov et al.<sup>42</sup>  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.62–7.24 (2H, m), 6.72 (1H, dd,  $J$  = 7.5 Hz,  $J$  = 1.5 Hz), 6.03–5.97 (1H, m), 5.23–5.18 (2H, m), 4.96 (1H, s), 3.40 (2H, d,  $J$  = 6.0 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  153.20, 135.46, 132.98, 130.59, 127.65, 117.54, 117.21, 112.92, 34.80. MS ( $m/z$ , Intensity): 214 ( $M^+$ , 100%), 199 (25%), 133 (60%), 118 (32%), 105 (28%).

**2.1.1.5. 2-Allyl-4-bromoanisole (11).** 2-Allyl-4-bromophenol (**10**; 1.47 g; 6.89 mmol) was mixed with potassium carbonate (6.0 g) and 30 ml of dry acetone under nitrogen atmosphere. After stirring for 15 min, methyl iodide (3.0 ml) was added and the resulting mixture was refluxed for 1.5 h. The reaction mixture was filtered to remove solid, and then concentrated to give 1.55 g yellowish crude product. Further purification by column chromatography on silica gel eluted with hexanes/EtOAc = 30/1 gave **11** as light yellowish oil (1.27 g, 81.1%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.31 (1H, dd,  $J$  = 8.5 Hz,  $J$  = 2.5 Hz), 7.27 (1H, d,  $J$  = 2.5 Hz), 6.75 (1H, d,  $J$  = 9.0 Hz), 5.98–5.93 (1H, m), 5.11–5.07 (2H, m), 3.83 (3H, s), 3.37 (2H, d,  $J$  = 3.5 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  156.38, 136.03, 132.41, 130.99, 129.88, 116.14, 112.72, 111.97, 55.61, 33.91. MS ( $m/z$ , Intensity): 229 ( $M^+$ , 15%), 201 (100%), 171 (25%), 148 (22%).

**2.1.1.6. 4-Methoxy-3-allyl-1-phenylboronic acid (12).** 2-Allyl-4-bromoanisole (2.85 g, 12.55 mmol) was dissolved in 50 ml of dry THF and cooled to  $-78^\circ\text{C}$  under nitrogen atmosphere, *n*-butyl lithium (2.5 M, 5.6 ml, 13.5 mmol) was added dropwise over 5 min. The mixture was stirred for 45 min, and then *tri*-isopropyl borate (17.96 g, 95.7 mmol) was added in one portion to the reaction mixture. The mixture was warmed up to room temperature for 2 h, then 50 ml of 0.5 N HCl was added. The organic layer was separated and aqueous layer was extracted with ether (50 ml  $\times$  3). The combined organic layer was dried over  $\text{MgSO}_4$  and concentrated in vacuo to give pale solid as crude product which was further purified by chromatography on silica gel and eluted with  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  = 30/1 to furnish 2.2 g of **12** as pale solid.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.13 (1H, dd,  $J$  = 8.0, 1.5 Hz), 8.00 (1H, d,  $J$  = 1.5 Hz), 7.01 (1H, d,  $J$  = 8.0 Hz), 6.15–6.07 (1H, m), 5.17–5.10 (2H, m), 3.94 (3H, s), 3.51 (2H, d,  $J$  = 6.4 Hz).  $^{13}\text{C}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  159.08, 137.56, 136.25, 134.58, 126.82, 115.76, 110.13, 55.67, 34.38.

**2.1.1.7. 1-Allyl-3-bromo-2-methoxymethoxybenzene(13).** 2-Allyl-6-bromophenol was prepared according to procedure reported by Palmer et al.<sup>43</sup> In a flask, 2-allyl-6-bromo-phenol (14.6 g) was mixed with 15 g of potassium carbonate in 250 ml of acetone under nitrogen atmosphere, and then chloromethyl methyl ether (6.0 g) was added. The mixture was refluxed overnight. After cooling to room temperature, the solid was filtered, and resulting solution was concentrated. The residue was purified by column chromatography on silica gel eluted with hexanes/EtOAc = 20/1 to yield 13 g of 1-allyl-3-bromo-2-methoxymethoxybenzene (**13**).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.45 (1H, dd,  $J$  = 8.0 Hz,  $J$  = 1.5 Hz), 7.17 (1H, dd,  $J$  = 8.0 Hz,  $J$  = 1.5 Hz), 6.98 (1H, t,  $J$  = 8.0 Hz), 6.04–5.96 (1H, m), 5.14–5.09 (2H, m), 5.12 (2H, s), 3.67 (3H, s), 3.54 (2H, d,

$J$  = 6.5 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ) 152.79, 136.52, 135.81, 131.56, 129.58, 125.65, 117.54, 116.34, 99.91, 57.81, 34.73. MS ( $m/z$ , Intensity): 258 ( $M^+$ , 25%), 225 (97%), 147 (100%).

**2.1.1.8. 3-Allyl-2-methoxymethoxy-1-phenylboronic acid (14).** 1-Allyl-3-bromo-2-methoxymethoxybenzene (**13**) (0.99 g, 3.9 mmol) was dissolved in 10 ml of dry THF and cooled to  $-78^\circ\text{C}$  under nitrogen atmosphere, *n*-butyl lithium (2.5 M, 2.2 ml, 5.5 mmol) was added dropwise over 5 min. The mixture was stirred for 45 min, and then *tri*-isopropyl borate (1.8 ml, 8.0 mmol) was added in one portion to the reaction mixture. The mixture was warmed up to room temperature for 2 h, then 20 ml of 0.1 N HCl was added. The organic layer was separated and aqueous layer was extracted with ether (25 ml  $\times$  2). The combined organic was dried over  $\text{MgSO}_4$  and concentrated in vacuo. The oily residue was purified by chromatography on silica gel eluted with hexane/EtOAc = 4/1, then EtOAc to give 0.93 g of **14** as colorless residue.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.73 (1H, dd,  $J$  = 7.5, 2.0 Hz), 7.35 (1H, dd,  $J$  = 7.5, 2.0 Hz), 7.19 (1H, t,  $J$  = 2.5 Hz), 6.04–5.96 (1H, m), 5.91 (2H, s), 5.16–5.07 (2H, m), 5.06 (2H, s), 3.57 (3H, s), 3.44 (2H, d,  $J$  = 6.0 Hz).  $^{13}\text{C}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  159.03, 137.82, 133.04, 132.04, 131.49, 123.89, 116.27, 100.13, 57.27, 34.33.

## 2.1.2. General procedure for the synthesis of honokiol analogs

In a 100 ml flask, 3-allyl-4-methoxyphenyl boronic acid (3.9 mmol),  $\text{Cs}_2\text{CO}_3$  (11.66 mmol), the corresponding bromo-allylphenol (3.54 mmol), and catalyst  $\text{Pd}(\text{Ph}_3\text{P})_4$  (0.35 mmol) were mixed in 45 ml of DME and 6 ml of water. The mixture was refluxed under nitrogen overnight. Following standard workup procedure, the product was isolated by chromatography on silica gel. The purities of all the synthetic compounds were >98% according to the proton NMR analysis.

### 2.1.2.1. 3,5'-Diallyl-2'-hydroxy-4-methoxy-1,1'-biphenyl (1)<sup>44,45</sup>

The reaction mixture was purified by column chromatography on silica gel eluted with hexanes/EtOAc = 30/1 to yield colorless oil residue.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.32 (1H, dd,  $J$  = 8.2 Hz, 2.2 Hz), 7.26 (1H, d,  $J$  = 2.2 Hz), 7.08 (1H, dd,  $J$  = 8.13, 2.2 Hz), 7.06 (1H, d,  $J$  = 2.1 Hz), 6.99 (1H, d,  $J$  = 8.2 Hz), 6.93 (1H, d,  $J$  = 8.13 Hz), 6.08–6.97 (2H, m), 5.16 (1H, s), 5.14 (1H, q,  $J$  = 1.74 Hz), 5.11–5.06 (3H, m), 3.91 (3H, s), 3.47 (2H, d,  $J$  = 6.63 Hz), 3.38 (2H, d,  $J$  = 6.75 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  157.06, 150.84, 137.81, 136.51, 132.17, 130.50, 130.20, 129.80, 129.05, 128.76, 127.90, 127.85, 115.84, 115.56, 115.53, 110.00, 55.56, 39.42, 34.28. MS ( $m/z$ ; Intensity): 279 ( $M^+$ , 100%), 264 (97%), 249 (32%). Total isolation yield: 52%.

### 2.1.2.2. 3'-Bromo-3,5'-diallyl-2'-hydroxy-4-methoxy-1,1'-biphenyl (2).

The reaction mixture was purified by column chromatography on silica gel eluted with hexanes/EtOAc = 15/1 to yield the first compound as yellowish oil residue.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.37 (1H, dd,  $J$  = 8.5, 2.0 Hz), 7.31 (1H, d,  $J$  = 2.0 Hz), 7.29 (1H, d,  $J$  = 2.0 Hz), 7.05 (1H, d,  $J$  = 2.0 Hz), 6.96 (1H, d,  $J$  = 8.5 Hz), 6.08–5.92 (2H, m), 5.66 (1H, s), 5.13–5.06 (4H, m), 3.90 (3H, s), 3.45 (2H, d,  $J$  = 3.5 Hz), 3.35 (2H, d,  $J$  = 3.0 Hz). MS ( $m/z$ , Intensity): 359 ( $M^+$ , 100%), 344 (20%). Total isolation yield: 15%.

### 2.1.2.3. 2,6-Di-(4'-methoxy-3'-allylphenyl)-phenol (3).

The same reaction mixture was purified by column chromatography on silica gel eluted with hexanes/ethyl acetate = 15/1 to yield the second compound as light yellowish oil residue.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.41 (2H, dd,  $J$  = 8.0, 2.0 Hz), 7.34 (2H, d,  $J$  = 2.0 Hz), 7.06 (2H, s), 6.97 (2H, d,  $J$  = 8.0 Hz), 6.08–5.90 (3H, m), 5.34 (1H, s), 3.90 (6H, s), 3.46 (4H, d,  $J$  = 6.5 Hz), 3.40 (2H, d,  $J$  = 6.5 Hz). MS ( $m/z$ , Intensity): 425 ( $M^+$ , 100%), 409.8 (30%), 395 (10%). Total isolation yield: 20%.

**2.1.2.4. 3,3'-Diallyl-4-methoxy-4'-hydroxy-1,1'-biphenyl (4).**

The reaction mixture was purified by column chromatography on silica gel eluted with hexanes/EtOAc = 10/1 to yield colorless oil residue.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.38 (1H, dd,  $J$  = 7.0, 2.0 Hz), 7.35–7.31 (3H, m), 6.92 (1H, d,  $J$  = 8.4 Hz), 6.88 (1H, d,  $J$  = 7.8 Hz), 6.13–6.03 (2H, m), 5.25–5.19 (2H, m), 5.13–5.07 (2H, m), 3.89 (3H, s), 3.49 (2H, d,  $J$  = 6.6 Hz), 3.46 (2H, d,  $J$  = 6.6 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  156.47, 153.23, 136.94, 136.23, 134.08, 133.35, 128.87, 128.85, 128.34, 126.23, 125.46, 125.41, 116.64, 116.15, 115.49, 110.65, 55.58, 35.39, 34.41. MS ( $m/z$ ; Intensity): 279 ( $M^-$ –1, 100%), 264 (59%), 249 (11%). Total isolation yield: 12%.

**2.1.2.5. 3,3'-Diallyl-2'-hydroxy-4-methoxy-1,1'-biphenyl (5).**

The coupling mixture was purified by column chromatography on silica gel eluted with hexanes/ethyl acetate = 20/1 to yield colorless oil residue which was further hydrolyzed to **5** by dissolved in 15 ml of THF and 15 ml of 6 N HCl and refluxed for 6 h. Reaction mixture was extracted with EtOAc (20 ml  $\times$  3) and the combined organic layer was dried over  $\text{MgSO}_4$ . Organic solvent was evaporated to give a colorless residue which was further purified by column chromatography on silica gel eluted with hexanes/EtOAc = 40/1 to give a colorless oil residue.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.31 (1H, dd,  $J$  = 7.5, 2.0 Hz), 7.26 (1H, d,  $J$  = 2.0 Hz), 7.13 (2H, td,  $J$  = 7.5, 2.0 Hz), 6.98 (1H, d,  $J$  = 8.5 Hz), 6.94 (1H, t,  $J$  = 7.5 Hz), 6.13–5.90 (2H, m), 5.36 (1H, s), 5.20–5.06 (4H, m), 3.90 (3H, s), 3.49 (2H, d,  $J$  = 6.6 Hz), 3.45 (2H, d,  $J$  = 6.7 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  157.04, 150.49, 136.78, 136.51, 130.66, 129.77, 129.30, 129.16, 128.36, 128.03, 127.99, 126.29, 120.34, 115.86, 115.80, 110.96, 55.55, 34.79, 34.29. MS ( $m/z$ ; Intensity): 279 ( $M^-$ –1, 100%), 264 (70%), 249 (30%). Total isolation yield: 53%.

**2.1.2.6. 3',5-Diallyl-2,2'-dihydroxy-1,1'-biphenyl (6).**

The reaction mixture was dissolved in 15 ml of THF and refluxed 6 h with 15 ml of 6 N HCl. After extraction with EtOAc (20 ml  $\times$  3), the organic layer was concentrated in vacuo. The residue was purified by column chromatography on silica gel eluted with hexanes/EtOAc = 4/1 to yield white solid.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.22 (1H, dd,  $J$  = 7.50, 2.0 Hz), 7.17 (1H, dd,  $J$  = 8.50, 2.0 Hz), 7.16 (1H, dd,  $J$  = 7.5, 2.0 Hz), 7.09 (1H, d,  $J$  = 2.0 Hz), 7.01 (1H, t,  $J$  = 7.5 Hz), 6.99 (1H, d,  $J$  = 8.5 Hz), 6.11–6.04 (1H, m), 6.02–5.94 (1H, m), 5.21–5.14 (2H, m), 5.13–5.07 (2H, m), 3.51 (2H, d,  $J$  = 6.50 Hz), 3.38 (2H, d,  $J$  = 6.51 Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  151.40, 151.10, 137.50, 136.47, 133.10, 131.14, 130.53, 130.11, 129.35, 127.19, 123.52, 123.46, 121.32, 116.64, 116.36, 115.85, 39.35, 34.99. MS ( $m/z$ ; Intensity): 265 ( $M^-$ –1, 100%), 252 (10%), 247 (8%). Total isolation yield: 21%.

**2.2. Cell culture**

The human cancer cell lines A549 (lung adenocarcinoma), UACC903 (melanoma) and HT-29 (colon) were purchased from American Type Culture Collection (Manassas, VA). All the cell lines were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 5.6 mmol/l glucose, glutamine at 37 °C in a humidified incubator with 5%  $\text{CO}_2$ .

**2.2.1. Cell proliferation and  $\text{IC}_{50}$  determination**

The culture cell lines UACC 903, A549 and HT-29 were seeded at  $5 \times 10^3$  cells/well in 96-well plate and after seeding cells were incubated at 37 °C in 5%  $\text{CO}_2$  for 24 h to allow cell attachment. Each cell line was treated at 6 concentrations (0, 0.5, 1.0, 5, 10, 25 and 50  $\mu\text{M}$ ) of honokiol analogs with a non-treatment control for 24 and 72 h, and the final concentration of DMSO were 0.2%. The cell viability was evaluated through the 3,4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay.<sup>46,47</sup> The tetrazolium compound MTS and an

electron coupling reagent, phenazine methosulfate (PMS), were used in the MTS assay. Viable cells reduced MTS to formazan, which was measured by determining absorbance at 492 nm using a spectrophotometer. Formazan production is time dependent and proportional to the number of viable cells. After incubation for the indicated time in the appropriate medium, 20  $\mu\text{l}$  of MTS/PMS mixture was added to each well. Then the cells were incubated for 3 h and the formazan product was quantified by measuring absorbance at 492 nm. The background absorbance from the control wells was subtracted from the actual absorbance value. Three duplicate assays were done for each experimental condition.  $\text{IC}_{50}$  values were calculated by GraphPad Prism version 4 for Windows (GraphPad Software, San Diego, CA; [www.graphpad.com](http://www.graphpad.com)).

**2.2.2. Synchronization and cell cycle analysis**

The effect of honokiol analogs on cell cycle distribution was determined by flow cytometry after staining the cells with DNA intercalating dye propidium iodide staining for DNA content measurement.<sup>18,19</sup> Approximately  $5 \times 10^6$  A549 cells were seeded into 6 well plate and allowed to attach by overnight incubation. Cells were synchronized by serum deprivation, when cells reached 40–50% cell confluency DMEM medium was added without serum and maintained in medium containing no serum for 48 h. After 48 h restimulated by replacing with fresh medium with 10% serum containing different (0, 0.5, 2.5 and 10  $\mu\text{M}$ ) concentrations of honokiol analogs such as **2** and **4** in similar volume of DMSO was added to the control (final concentration of DMSO 0.2%). Plates were incubated for 48 h at 37 °C. After that floating and adherent A549 cells were collected by treatment with 0.05% trypsin and pelleted, washed with cold PBS. Cells were fixed in 70% ethanol at –20 °C overnight. Following overnight fixation cells were washed twice with ice cold PBS. Afterwards, cells were resuspended 1 ml of 0.1% Triton X-100 in PBS supplemented with 50  $\mu\text{g}/\text{ml}$  PI, and 100  $\mu\text{g}$  of DNase free RNase A. Resuspended cells were then stored in the dark at room temperature for 30 min prior to analysis by flow cytometry for the cell cycle specificity of apoptotic cells. Untreated cells were used as the negative controls. Stained cells were then analyzed using FACS (FACScan; BD), and at least 100,000 cells were counted for each sample.

**2.2.3. Western blot analysis**

Immunoblotting was performed as previously described.<sup>18,19</sup> For determination of the total amount of CDK1 and cyclin B1, A549 cells ( $5 \times 10^6$ ) were seeded onto 6 well plate and incubated overnight to allow cells attachment and subsequently synchronized by treatment with nocodazole (0.5  $\mu\text{g}/\text{ml}$ ) for 15 h. Thereafter, the plates were incubated with analogs **2** and **4** (0, 0.5, 1.0, 2.0 and 5.0  $\mu\text{M}$ ) or the DMSO for control, the final concentration of DMSO was 0.2% and the plates were incubated for 18 h at 37 °C. The plates were washed with ice cold PBS and then harvested in 600  $\mu\text{l}$  RIPA buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40 and 0.25% sodium deoxycholate), supplemented with a protease inhibitor cocktail (1 mM AEBSF, 800 nM Aprotatin, 50  $\mu\text{M}$  Bestatin, 15  $\mu\text{M}$  E64, 20  $\mu\text{M}$  leupeptin, 10  $\mu\text{M}$  pepstatin A and 3 mM phenylmethylsulfonyl fluoride), and incubated on ice for 30 min. Supernatant was recovered after removing cell debris by centrifugation at 12–14 K rpm for 15 min at 4 °C. Protein concentration was determined with BCA protein assay reagents. Equal amounts of protein (40  $\mu\text{g}$ ) for each sample were resolved on a 12% SDS–polyacrylamide gel and transferred onto a nitrocellulose membrane. The membrane was blocked for 1 h with 5% skim milk in Tris–buffered saline–Tween (TBST) buffer (100 mM Tris, 150 mM NaCl and 0.1% Tween 20) at room temperature. After blocking membrane were incubated with primary antibodies, a rabbit polyclonal CDK1 antibody against human CDK1 and a rabbit polyclonal antibody against human cyclin B1 overnight at 4 °C. The



membrane was washed with TBST buffer and incubated with secondary antibody anti-rabbit IgG (H+L) peroxidase conjugate for 2 h at room temperature. Enhanced chemoluminescence reagents were used to visualize the protein bands. Each experiment was performed three times (different cell passages). The relative protein band intensities were determined by using the ImageJ 1.44 software (<http://imagej.nih.gov/ij/index.html>).

### 3. Result

#### 3.1. Synthesis of honokiol analogs

We prepared honokiol analogs with the phenol group replaced by methoxy group in A-ring and/or by changing the substitution pattern on B-ring of the biphenyl structure. A total of six honokiol analogs were synthesized and their SAR evaluated (Fig. 1). Our synthetic approach for honokiol analogs was based on the Pd-catalyzed Myaura–Suzuki coupling reaction<sup>36</sup> which provides the flexibility of changing substitution on both rings of biphenyl moiety and also makes synthetic scheme extremely converge.

The syntheses of analogs **1–6** are illustrated in Scheme 1. The important building block for the synthesis are substituted isomers of 4-allyl-2-bromophenol (**8**) and 4-allyl-2,6-dibromophenol (**9**) which were prepared independently from same reagent 1,3-dibromo-5,5-dimethylhydantoin (DBDMH)<sup>48,49</sup> under different reaction condition (Scheme 2). The common reagent for honokiol analogs **1–5** is 3-allyl-4-methoxyphenyl boronic acid (**12**). Compound **11** was prepared from Claisen Rearrangement of 1-allyloxy-4-bromobenzene<sup>50</sup> according to standard procedure<sup>43</sup> to give 2-allyl-4-bromophenol **10**. Standard methylation with methyl iodide and potassium carbonate yielded 2-allyl-4-bromo-anisole **11**. Further treatment of **11** with *n*-BuLi followed by *tri*-isopropyl borate<sup>43</sup> gave the desire Suzuki coupling reagent **12**.


Claisen rearrangement of 1-allyloxy-2-bromobenzene to the corresponding 1-allyl-3-bromo-2-phenol was carried out according to procedure reported by Palmer et al.<sup>43</sup> under mild condition, the

compound was not isolated but further reacted with methyl methoxy chloride (MOMCl) to give excellent yield of 1-allyl-3-bromo-2-methoxymethoxybenzene (**13**). Conversion of compound **13** to the corresponding boronic acid **14** was carried out in the similar fashion as for compound **12** with *n*-BuLi and *tri*-*iso*-propyl borate.<sup>43</sup>


The Suzuki coupling reaction between the two moieties was carried out by standard conditions using Pd(PPh<sub>3</sub>)<sub>4</sub> and Cs<sub>2</sub>CO<sub>3</sub>.<sup>43</sup> The yields of this cross-coupling varied depending on different building blocks deployed; we obtained yields from 12% to as high as 52% depending on the substitution pattern on ring B. Synthesis of **6** was carried out with the coupling of 2-bromo-4-allylphenol (**8**)<sup>48,51</sup> and 3-allyl-2-methoxymethoxy-1-phenyl boronic acid (**14**).<sup>43,48</sup> The MOM group was removed by refluxing the coupled intermediate in 6 N HCl/THF mixtures. The two steps synthesis gave total yield of 21%. All the honokiol analogs were characterized by proton NMR and MS.

#### 3.2. Inhibition of human cancer cells growth by honokiol analogs

Literature reports have shown that honokiol inhibit proliferation, suppress tumor growth and induce apoptosis<sup>18,19,46</sup> in human cancer cells. We first tested for growth inhibitory activity of the newly synthesized analogs in three different human cancer cell lines UACC903, A549 and HT-29, by MTS assay. The cells were maintained in the presence or absence of different concentration (0–50 μM) of honokiol analogs for 24 and 72 h. Cells were treated with increasing concentrations of honokiol analogs. Honokiol analogs significantly inhibited cell viability, as evidenced by a MTS assay, in a time and concentration-dependent manner. The IC<sub>50</sub> of honokiol analogs in different cancer cells were examined and the results are shown in Table 1. All new analogs gave relatively low IC<sub>50</sub> values as compared to honokiol in all three cancer cell lines, except that analogs **1**, **5**, and **6** were less effective in UACC903 cells. Analog **2** and **4** were consistently the most cytotoxic than honokiol and other analogs in all three cell lines tested. There were no sig-



Scheme 1. Synthetic of honokiol analogs.



Scheme 2. Syntheses of Suzuki reagents.

nificant differences in growth inhibition between analog **2** and **4** (Table 1).

### 3.3. Effects on cell cycle distribution

Honokiol arrests cells in the G1 phase.<sup>18,19</sup> We examined whether the new honokiol analogs can regulate the cell cycle similar to honokiol. Therefore, the effect of these analogs on the cell

cycle distribution of A549 cells was determined. Flow cytometry was employed to examine the changes in DNA content. Synchronized A549 cells were treated with analog **2** and **4** at various concentrations. We observed that both analog **2** and **4** treated A549 cells induced G0–G1 cell cycle arrest as observed in the case of honokiol (Fig. 2A–D). Further analysis indicated that **2** and **4** (2.5  $\mu\text{M}$  and 10  $\mu\text{M}$ ) induced the accumulation of significant number of cells in the G0–G1 phase of the cell cycle (Table 2). These

**Table 1**  
IC<sub>50</sub> ( $\mu\text{M}$ ) values of honokiol analogs in human cancer cell lines (24 and 72 h exposure)<sup>a</sup>

Analog	UACC903		A549		HT-29	
	24 h	72 h	24 h	72 h	24 h	72 h
<b>1</b>	37.68 $\pm$ 27.86	24.13 $\pm$ 19.75	1.56 $\pm$ 0.88	1.24 $\pm$ 0.77	22.45 $\pm$ 17.20	14.13 $\pm$ 10.84
<b>2</b>	2.98 $\pm$ 1.78	1.29 $\pm$ 0.80	1.73 $\pm$ 0.88	1.04 $\pm$ 0.60	3.99 $\pm$ 2.62	1.87 $\pm$ 1.23
<b>3</b>	3.94 $\pm$ 4.28	2.93 $\pm$ 1.73	1.74 $\pm$ 1.10	1.25 $\pm$ 0.78	16.09 $\pm$ 12.57	11.39 $\pm$ 9.14
<b>4</b>	3.05 $\pm$ 1.83	1.39 $\pm$ 0.84	2.47 $\pm$ 1.32	1.99 $\pm$ 1.09	3.19 $\pm$ 1.78	2.00 $\pm$ 1.27
<b>5</b>	29.04 $\pm$ 22.37	24.66 $\pm$ 18.26	11.29 $\pm$ 7.78	6.28 $\pm$ 4.42	16.24 $\pm$ 13.30	11.50 $\pm$ 8.92
<b>6</b>	22.28 $\pm$ 15.92	17.39 $\pm$ 12.60	2.04 $\pm$ 1.15	1.08 $\pm$ 0.66	17.38 $\pm$ 14.02	12.37 $\pm$ 10.31
Honokiol	7.45 $\pm$ 5.28	5.10 $\pm$ 3.60	12.51 $\pm$ 7.94	7.75 $\pm$ 4.96	23.05 $\pm$ 18.04	13.24 $\pm$ 10.66

<sup>a</sup> Cells were incubated in the presence or absence of honokiol analogs at different concentrations ( $\mu\text{M}$ ). Effective concentration of honokiol analogs that inhibited cell growth to 50% of control (IC<sub>50</sub>) in three different cancer cell lines was determined (GraphPad Prism version 4 for Windows) using the MTS assay. Values are given as mean  $\pm$  SD of three separate assays.

results indicated that the observed growth inhibitory effects of **2** and **4** in A549 cells are due to cell cycle arrest, and is accompanied by a decrease in both S phase and G2-M phase cells in a concentration-dependent manner (Table 2).

### 3.4. Effects of honokiol analogs on inhibition of CDK1 and cyclin B1 level in A549 cells

The profound effect of **2** and **4** on cell cycle distribution led to the question of how they interact with cell cycle regulatory machinery, namely CDKs and cyclins. In order to address this question, we investigated CDK1 and cyclin B1, the two important regulatory proteins, as initial targets.<sup>21,32,52,53</sup> We examined the ability of analogs **2** and **4** to inhibit the total cellular content of human CDK1 and cyclin B1 proteins in human lung cancer cells (A549). The cells were arrested and released, and then incubated for 18 h with four different concentrations of **2** and **4**. The total cellular content of human CDK1 and cyclin B1 proteins was determined by Western blot analysis using polyclonal antibodies. A549 cells treated with analogs **2** and **4** caused a rapid decrease in CDK1 and cyclin B1 protein level in a concentration-dependent manner (Fig. 3B and C). In comparison, honokiol was less effective (Fig. 3A). A significant reduction was observed in the groups


**Table 2**

Cell cycle distribution (%) with honokiol analogs in A549 cells after 48 h treatment<sup>a</sup>


Compound	Concentration	G0/G1 (%)	S (%)	G2/M (%)
DMSO	Control	40.6 ± 4.6	41.2 ± 3.1	18.2 ± 2.1
Honokiol	0.5 μM	50.5 ± 5.3	37.9 ± 2.3	11.6 ± 1.7
	2.5 μM	61.1 ± 3.1	28.1 ± 1.5	10.8 ± 4.3
	10 μM	72.9 ± 5.2	21.7 ± 4.2	5.4 ± 1.8
	20 μM	82.8 ± 2.4	14.3 ± 3.3	2.8 ± 0.6
<b>2</b>	0.5 μM	55.8 ± 2.9	32.8 ± 2.8	11.4 ± 1.8
	2.5 μM	63.1 ± 3.6	30.6 ± 1.5	6.3 ± 2.0
	10 μM	76.4 ± 2.6	20.7 ± 14.3	3.0 ± 0.7
	20 μM	82.8 ± 2.4	14.3 ± 3.3	2.8 ± 0.6
<b>4</b>	0.5 μM	69.8 ± 1.1	23.0 ± 5.2	7.2 ± 0.9
	2.5 μM	75.7 ± 3.5	20.2 ± 2.7	4.2 ± 1.0
	10 μM	82.8 ± 2.4	14.3 ± 3.3	2.8 ± 0.6
	20 μM	82.8 ± 2.4	14.3 ± 3.3	2.8 ± 0.6

<sup>a</sup> Approximately  $5 \times 10^6$  A549 cells were starved by serum deprivation, and then incubated in the presence or absence of analog **2** and **4** for 48 h. After incubation, cells were fixed, treated with RNase A and stained for DNA with propidium iodide. Cell cycle distribution was determined by FACS analysis. Results are presented as a percentage of the total cell population. The whole experiment was repeated twice. Values are given as mean ± SD.


treated with **2** and 5 μM of analogs **2** and **4** (Fig. 3B and C). The concentration dependent change of CDK1 and cyclin B1 protein level is comparable to the results for honokiol.



**Figure 2.** Percentage of cell cycle distribution in A549 cells treated for 48 h. (A) Percentage of cells distribution by honokiol treatment, (B) Percentage of cell distribution by analog **2** treatment and (C) Percentage of cell distribution by analog **4** treatment. (D) Percentage of cell distribution by DMSO treatment. The results are presented as means (±SD) and similar results were observed in two independent experiments.



**Figure 3.** Effects of honokiol analogs on CDK1 and cyclin B1 proteins. A549 cells were treated with honokiol analogs with 0.0, 0.5, 1.0, 2.0 and 5.0  $\mu\text{M}$  for 18 h. After that cell lysates were prepared and the level of CDK1 and cyclin B1 proteins were determined by western blot analysis. **A.** Cells treated with honokiol, **B.** Cells treated with **2** and (**C**) Cells treated with **4**. The experiments were repeated more than twice using independently prepared lysates with similar results.  $\beta$ -Actin is shown as a loading control. The blots were stripped and reported with *anti-actin* antibody to normalize for differences in protein loading.



**Figure 4.** Percentage of CDK1 and cyclin B1 inhibition in A549 cells treated with honokiol analogs. Western blot analysis for CDK1 and cyclin B1 using whole cell lysates from A549 cells treated with honokiol analogs for the indicated concentrations for 18 h. Western blotting for CDK1 and cyclin B1 proteins was done more than two times and the results were consistent. (**A**) Percentage of CDK1 and cyclin B1 inhibition cells treated with honokiol, (**B**) Percentage of CDK1 and cyclin B1 inhibition cells treated with **2** and (**C**) Percentage of CDK1 and cyclin B1 inhibition cells treated with **4**.

#### 4. Discussion

The SAR studies on honokiol analogs have been reported in the literature with varying success.<sup>6,36,54–56</sup> Our goal of using SAR to enhance the activity of honokiol as antitumor agents is based on observed pharmacological properties of honokiol and our hypothesis is that the non-availability of phenol group in the A-ring would

enhance honokiol anti-tumor activity. Our investigation is to gain insights into the interaction of newly prepared honokiol analogs and the mechanism of cell cycle regulation using A549 human lung cancer cells as a model. To validate our hypothesis, we prepared six modified honokiol analogs and their cytotoxicity tested *in vitro* in human cancer cell lines A549, UACC903 and HT-29 for different time and concentration dependent manner. Our results show that



treatment of honokiol analogs for 24 and 72 h induces a rapid growth arrest in A549, UACC903 and HT-29 cell lines. This result is comparable with previous studies with honokiol alone.<sup>8,9,11,54</sup> The blocking of hydroxyl group by methylation on A-ring analogs, such as analogs **2** and **4** showed higher cytotoxicity for all three cell lines. These results support our hypothesis that making phenol group in A-ring unavailable would enhance activity of honokiol. Specifically, both **2** and **4** showed lower IC<sub>50</sub> in A549 cell line compared with other analogs and honokiol. For further investigation we selected **2** and **4** to elucidate underlying mechanisms of growth inhibition, cell cycle arrest and apoptosis. We studied the cell cycle distribution and observed significantly induced a G1 phase arrest of cells after treatment of **2** and **4** in the synchronized A549 cell line compared to the untreated control cells.

The intracellular events governing the cell division cycle are conserved in many eukaryotic cell types. The kinase activities of CDKs are the driving force for the progression of the cell cycle through the transition check points, due to their ability to activate cyclins, essential components of cyclin and CDK complexes.<sup>57</sup> Studies have documented a G<sub>1</sub> phase cell cycle arrest by honokiol in human prostate cancer<sup>18</sup> and VSMC cells<sup>19</sup> treatment at concentrations within the range of analogs **2** and **4** used in the present study. The present study reveals that exposure of A549 cells to pharmacologically achievable concentrations of honokiol analogs **2** and **4** showed growth suppression and G0–G1 phase arrest (Fig. 2A–D). The G0–G1 phase cell cycle arrest is modest as evidenced by 10–50% increase in percentage of G0–G1 phase over DMSO treated control (Table 2). The observation is consistent with that reported for honokiol and may suggest that the mechanism of G0–G1 phase arrest for honokiol, **2**, and **4** is similar.

To further understand interaction between honokiol analogs and cell cycle regulatory proteins, we determined total protein levels of CDK1 and cyclin B1 after treating A549 cells with honokiol analogs. Our results indicated that analogs **2** and **4** significantly lowered the protein levels of CDK1 and cyclin B1 in a concentration dependent manner (Fig. 4). Taken together, the cell cycle distribution studies and the lowering of CDK1 and cyclin B1 may imply that other CDKs are also involved in the cell cycle arrest. The protein kinase CDK1 and cyclin B1 play a crucial role in the onset of mitosis in human cells. The CDK1 and cyclin B1 complex accumulates in the cytoplasm during the G2 phase, being translocated into the nucleus at the beginning of mitosis.<sup>58</sup> The decrease in cyclin B1 levels leads to inhibition of cell division owing to low CDK1 activity. Therefore, a sub-cytotoxic concentration of **2** and **4** are likely to inhibit CDK1 activity through a decrease in the levels of cyclin B1. Suppression of CDK1 activity not only inhibits cell division, but also allows the assembly of pre-replication complexes for licensing the DNA for another round of replication.<sup>59</sup>

The introduction of methoxy group on the A-ring of honokiol increases the inhibitory activity in human cancer cell lines. The cell cycle passage in mammalian cells is regulated by a complex system of activating and inhibiting factors. The different cyclin-dependent kinases act in distinct phases of the cell cycle. Thus, potent and selective inhibitors of CDKs might induce different effects on the cell cycle distribution, depending on the respective phase in which the cells are targeted. The results of cell cycle distribution study indicated that analogs **2** and **4** can interfere with cell cycle regulation at G0–G1 phase. In addition, the protein levels of CDK1 and cyclin B1 were reduced significantly upon treatment of **2** and **4** which indicated both analogs can interfere with the regulation of cell cycle at M phase. Taken together, these results suggest that honokiol analogs could exert control at two critical stages of cell cycle, namely, G0–G1 and M phase. It is also interesting to note that recently CDK1 was discovered to be able to drive the mammalian cell cycle.<sup>21</sup> Therefore, results of the present study are a significant step forward in understanding the activity of **2** and **4**; they also shed

new light on the molecular mechanisms underlying the potent effects of the **2** and **4**. Honokiol was shown to cause apoptosis in cancer cell lines that have defective p53 gene and activated ras gene.<sup>60</sup> Honokiol can also induced cyclophilin D and cause death in cells with wild-type p53.<sup>60</sup> Further studies on other human cancer cell lines will be tested in the future.

This investigation confirmed that blocking the possible oxidation of the phenolic hydroxyl group in the biphenyl group skeleton will enhance the anti-tumor activity of honokiol. The newly synthesized analogs are capable of arresting the progress of cell cycle at G0–G1 phase. These studies provide experimental evidence that newly synthesized honokiol analogs are potent tumor cell growth inhibitors and they are also capable of inhibiting CDK1 and cyclin B1, important cell cycle regulatory proteins. In conclusion, honokiol analogs **2** and **4** are potent anti-cancer agents that exhibit strong inhibitory property toward cell growth at lower concentration than the honokiol, and induce cell cycle arrest at G0–G1 phase. Most importantly, both analogs effectively lower CDK1 and cyclin B1 protein levels in the treated cells, which suggest that they interfered with key kinases that promote mitosis. The mechanistic bases for these apparent synergies need further investigation.

## Acknowledgments

The author thanks the financial support from Penn State Hershey Cancer Institute (J.M.L.). This study was supported in part by the NCI Grant R03-CA143999 (A.K.S.). The authors like to thank the Core Research Facilities at College of Medicine, Pennsylvania State University for recording of flow cytometry and NMR facility for NMR spectra. In addition, we appreciate Dr. Kun-Ming Chen for obtaining mass spectra for our compounds.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.2012.03.062>.

## References and notes

- Fujita, M.; Itokawa, H.; Sashida, Y. *Chem. Pharm. Bull. (Tokyo)* **1972**, *20*, 212.
- Liou, K. T.; Shen, Y. C.; Chen, C. F.; Tsao, C. M.; Tsai, S. K. *Eur. J. Pharmacol.* **2003**, *475*, 19.
- Teng, C. M.; Chen, C. C.; Ko, F. N.; Lee, L. G.; Huang, T. F.; Chen, Y. P.; Hsu, H. Y. *Thromb. Res.* **1988**, *50*, 757.
- Lo, Y. C.; Teng, C. M.; Chen, C. F.; Chen, C. C.; Hong, C. Y. *Biochem. Pharmacol.* **1994**, *47*, 549.
- Amblard, F.; Delinsky, D.; Arbiser, J. L.; Schinazi, R. F. *J. Med. Chem.* **2006**, *49*, 3426.
- Amblard, F.; Govindarajan, B.; Lefkove, B.; Rapp, K. L.; Detorio, M.; Arbiser, J. L.; Schinazi, R. F. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 4428.
- Fong, W. F.; Tse, A. K.; Poon, K. H.; Wang, C. *Int. J. Biochem. Cell Biol.* **2005**, *37*, 427.
- Wang, T.; Chen, F.; Chen, Z.; Wu, Y. F.; Xu, X. L.; Zheng, S.; Hu, X. *World J. Gastroenterol.* **2004**, *10*, 2205.
- Park, E. J.; Zhao, Y. Z.; Kim, Y. H.; Lee, B. H.; Sohn, D. H. *Planta Med.* **2005**, *71*, 82.
- Yang, S. E.; Hsieh, M. T.; Tsai, T. H.; Hsu, S. L. *Biochem. Pharmacol.* **2002**, *63*, 1641.
- Battle, T. E.; Arbiser, J.; Frank, D. A. *Blood* **2005**, *106*, 690.
- Konoshima, T.; Kozuka, M.; Tokuda, H.; Nishino, H.; Iwashima, A.; Haruna, M.; Ito, K.; Tanabe, M. *J. Nat. Prod.* **1991**, *54*, 816.
- Nagase, H.; Ikeda, K.; Sakai, Y. *Planta Med.* **2001**, *67*, 705.
- Bai, X.; Cerimele, F.; Ushio-Fukai, M.; Waqas, M.; Campbell, P. M.; Govindarajan, B.; Der, C. J.; Battle, T.; Frank, D. A.; Ye, K.; Murad, E.; Dubiel, W.; Soff, G.; Arbiser, J. L. *J. Biol. Chem.* **2003**, *278*, 35501.
- Ishitsuka, K.; Hideshima, T.; Hamasaki, M.; Raje, N.; Kumar, S.; Hideshima, H.; Shiraishi, N.; Yasui, H.; Roccaro, A. M.; Richardson, P.; Podar, K.; Le, G. S.; Chauhan, D.; Tamura, K.; Arbiser, J.; Anderson, K. C. *Blood* **2005**, *106*, 1794.
- Vaid, M.; Sharma, S. D.; Katiyar, S. K. *Carcinogenesis* **2010**, *31*, 2004.
- Maruyama, Y.; Kuribara, H.; Morita, M.; Yuzurihara, M.; Weintraub, S. T. *J. Nat. Prod.* **1998**, *61*, 135.
- Hahm, E. R.; Singh, S. V. *Mol. Cancer Ther.* **2007**, *6*, 2686.
- Lee, B.; Kim, C. H.; Moon, S. K. *FEBS Lett.* **2006**, *580*, 5177.
- Ahn, K. S.; Sethi, G.; Shishodia, S.; Sung, B.; Arbiser, J. L.; Aggarwal, B. B. *Mol. Cancer Res.* **2006**, *4*, 621.

21. Satyanarayana, A.; Kaldis, P. *Oncogene* **2009**, *28*, 2925.
22. Ortega, S.; Prieto, I.; Odajima, J.; Martin, A.; Dubus, P.; Sotillo, R.; Barbero, J. L.; Malumbres, M.; Barbacid, M. *Nat Genet.* **2003**, *35*, 25.
23. Tetsu, O.; McCormick, F. *Cancer Cell* **2003**, *3*, 233.
24. Hirai, H.; Kawanishi, N.; Iwasawa, Y. *Curr. Top. Med Chem* **2005**, *5*, 167.
25. Knockaert, M.; Greengard, P.; Meijer, L. *Trends Pharmacol. Sci.* **2002**, *23*, 417.
26. Krek, W.; Nigg, E. A. *EMBO J.* **1991**, *10*, 305.
27. Shen, M.; Feng, Y.; Gao, C.; Tao, D.; Hu, J.; Reed, E.; Li, Q. Q.; Gong, J. *Cancer Res* **2004**, *64*, 1607.
28. Pines, J.; Hunter, T. *Cell* **1989**, *58*, 833.
29. Gong, J.; Traganos, F.; Darzynkiewicz, Z. *Cell Growth Differ.* **1995**, *6*, 1485.
30. Viallard, J. F.; Lacombe, F.; Dupouy, M.; Ferry, H.; Belloc, F.; Reiffers, J. *Exp Cell Res* **1999**, *247*, 208.
31. Yuan, J.; Yan, R.; Kramer, A.; Eckerdt, F.; Roller, M.; Kaufmann, M.; Strebhardt, K. *Oncogene* **2004**, *23*, 5843.
32. Yuan, J.; Kramer, A.; Matthess, Y.; Yan, R.; Spankuch, B.; Gatje, R.; Knecht, R.; Kaufmann, M.; Strebhardt, K. *Oncogene* **2006**, *25*, 1753.
33. Soria, J. C.; Jang, S. J.; Khuri, F. R.; Hassan, K.; Liu, D.; Hong, W. K.; Mao, L. *Cancer Res.* **2000**, *60*, 4000.
34. Hassan, K. A.; Ang, K. K.; El-Naggar, A. K.; Story, M. D.; Lee, J. I.; Liu, D.; Hong, W. K.; Mao, L. *Cancer Res.* **2002**, *62*, 6414.
35. Yoshida, T.; Tanaka, S.; Mogi, A.; Shitara, Y.; Kuwano, H. *Ann. Oncol.* **2004**, *15*, 252.
36. Esumi, T.; Makado, G.; Zhai, H.; Shimizu, Y.; Mitsumoto, Y.; Fukuyama, Y. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 2621.
37. Hughes, M. F.; Hall, L. L. *Xenobiotica* **1995**, *25*, 873.
38. Eastmond, D. A.; Smith, M. T.; Ruzo, L. O.; Ross, D. *Mol. Pharmacol.* **1986**, *30*, 674.
39. Bohmdorfer, M.; Maier-Salamon, A.; Taferner, B.; Reznicek, G.; Thalhammer, T.; Hering, S.; Hufner, A.; Schuhly, W.; Jager, W. *J. Pharm. Sci.* **2011**, *100*, 3506.
40. Kwak, J. H.; Cho, Y. A.; Jang, J. Y.; Seo, S. Y.; Lee, H.; Hong, J. T.; Han, S. B.; Lee, K.; Kwak, Y. S.; Jung, J. K. *Tetrahedron* **2011**, *67*, 9401.
41. Alam, A.; Takaguchi, Y.; Ito, H.; Yoshida, T.; Tsuboi, S. *Tetrahedron* **2005**, *61*, 1909.
42. Sviridov, S. I.; Vasil'ev, A. A.; Sergovskaya, N. L.; Chirskaya, M. V.; Shorshnev, S. V. *Tetrahedron* **2006**, *62*, 2639.
43. Palmer, F. N.; Lach, F.; Poriel, C.; Pepper, A. G.; Bagley, M. C.; Slawin, A. M. Z.; Moody, C. J. *Org. Biomol. Chem.* **2005**, *3*, 3805.
44. Denton, R. M.; Scragg, J. T.; Saska, J. *Tetrahedron Lett.* **2011**, *52*, 2554.
45. Taferner, B.; Schuehly, W.; Huefner, A.; Baburin, I.; Wiesner, K.; Ecker, G. F.; Hering, S. *J. Med. Chem.* **2011**, *54*, 5349.
46. Wu, F.; Zhang, W.; Li, L.; Zheng, F.; Shao, X.; Zhou, J.; Li, H. *Eur. J. Pharmacol.* **2011**, *654*, 117.
47. Patterson, C.; Perrella, M. A.; Endege, W. O.; Yoshizumi, M.; Lee, M. E.; Haber, E. *J. Clin. Invest.* **1996**, *98*, 490.
48. Alam, A.; Takaguchi, Y.; Ito, H.; Yoshida, T.; Tsuboi, S. *Tetrahedron* **2005**, *61*, 1909.
49. Alam, A. *Synlett* **2005**, 2403–2404.
50. Kurosawa, W.; Kobayashi, H.; Kan, T.; Fukuyama, T. *Tetrahedron* **2004**, *60*, 9615.
51. Mel'kanovitskaya, S. G. *Uzb. Khim. Zh.* **1967**, *11*, 34.
52. Padmakumar, V. C.; Aleem, E.; Berthet, C.; Hilton, M. B.; Kaldis, P. *Mol. Cell. Biol.* **2009**, *29*, 2582.
53. Matthess, Y.; Raab, M.; Sanhaji, M.; Lavrik, I. N.; Strebhardt, K. *Mol. Cell. Biol.* **2010**, *30*, 5726.
54. Kong, Z. L.; Tzeng, S. C.; Liu, Y. C. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 163.
55. Zhai, H.; Nakade, K.; Oda, M.; Mitsumoto, Y.; Akagi, M.; Sakurai, J.; Fukuyama, Y. *Eur. J. Pharmacol.* **2005**, *516*, 112.
56. Luo, Y.; Xu, Y.; Chen, L.; Hu, J.; Peng, C.; Xie, D.; Shi, J.; Huang, W.; Xu, G.; Peng, M.; Han, J.; Li, R.; Yang, S.; Wei, Y. *Bioorg. Med Chem Lett.* **2009**, *19*, 4702.
57. Jacks, T.; Weinberg, R. A. *Nature* **1996**, *381*, 643.
58. Takizawa, C. G.; Weis, K.; Morgan, D. O. *Proc. Natl. Acad. Sci. U.S.A* **1999**, *96*, 7938.
59. Diffley, J. F. *Curr. Biol.* **2004**, *14*, R778.
60. Fried, L.; Arbiser, J. L. *Antioxid. Redox. Signal.* **2009**, *11*, 1139.